360biolabs: Integrated Bioanalysis for Complex Early-Phase Studies
360biolabs' 10th anniversary
The 10 Series: A decade of enabling future medicines
A decade of enabling future medicines through science-driven laboratory execution with integrated Pharmacokinetics, Pharmacodynamics, Immunogenicity, Biomarkers, Flow Cytometry, PBMC processing, and Central Laboratory Services, helps early-phase sponsors turn complex protocols into reliable data.
In this blog, we dive into an example of an integrated complex bioanalysis case study on complex gene therapy from sample collection through to quality-reviewed data delivery.
Complex Science Needs Connected Execution
Complex early-phase studies need more than assay capacity. They need an integrated scientific plan that connects drug exposure, biological response, immune monitoring, sample logistics and data quality from the first collection visit through to final data transfer.
As 360biolabs marks ten years of enabling future medicines, one lesson from early-phase development is clear: the scientific question rarely sits within one assay. Our services support advanced therapeutics; pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarkers and cellular endpoints, often needing to be planned together.
The value of an experienced bioanalytical partner is not only technical capability. It is the ability to align methods, matrices, sample handling, timelines and quality expectations so sponsors can reach the next development decision with confidence.
An Early-Phase Autoimmune Example
A recent early-phase autoimmune program required coordinated support across bioanalysis, PBMC processing, central laboratory services, study coordination, clinical kit management, biobanking and controlled sample logistics. Studies for autoimmune and immune-mediated often require connected PK, PD, immunogenicity, biomarker and cellular endpoint strategies, all supported by our team of skilled scientists.
The program needed methods that could measure exposure, assess biological response, monitor immune effects and preserve time-sensitive samples. It also required practical execution across study start-up, sample collection, accessioning, storage, shipment and quality-reviewed data delivery.
Pharmacokinetics (PK): Measuring Exposure with the Right Method
PK assessment helps sponsors understand how drug exposure changes over time. In early-phase studies, this information can inform dose selection, schedule planning and interpretation of safety and response data.
For complex modalities, PK may require more than one analytical approach. Ligand-binding assays, immunoassays, LC-MS/MS and molecular methods can each be relevant depending on the analyte, matrix and context of use.
Method selection should account for expected concentration range, sample type, interference risk, stability, turnaround time and regulatory expectations. This is where early scientific planning matters. The right approach protects data quality before the first clinical sample is collected.
Pharmacodynamics (PD): Linking Treatment to Biological Response
PD endpoints help answer a different question: is the investigational therapy engaging the intended biology? In early development, this evidence can be critical for understanding the mechanism, refining the bioanalytical strategy and planning later clinical studies.
PD strategies may include soluble biomarkers, molecular markers and cellular phenotyping. High-parameter flow cytometry can add important single-cell resolution by identifying changes in immune cell subsets and functional markers.
When PK and PD are planned together, sponsors gain a clearer view of exposure-response relationships. This supports a stronger interpretation of early clinical data, especially when biological activity may be observed before clinical efficacy can be assessed.
Immunogenicity and Immune Monitoring
Immune responses can influence exposure, safety interpretation and downstream development planning. For this reason, immunogenicity testing should be considered early and aligned with PK, PD and sample logistics.
Anti-drug antibody assessments, immune complex measurements and relevant biomarker panels can help contextualise study findings. The exact design depends on therapeutic modality, mechanism, matrix and study objectives.
The critical requirement is coordination. Immunogenicity and immune monitoring endpoints often depend on precise collection timing, appropriate sample handling and consistent documentation across sites and laboratory teams.
Central Laboratory Services Protect the Sample Journey
Scientific quality starts before a sample reaches the assay bench. Complex early-phase protocols require clear collection instructions, reliable kit configuration, controlled logistics and traceable sample management.
In an integrated model, central laboratory services support the full sample journey. This can include laboratory manuals, protocol-specific collection kits, site coordination, sample accessioning, chain-of-custody management, biobanking, sample retrieval, onward shipment and data transfer preparation.
PBMC processing and cryogenic storage add another layer of operational discipline. Time-sensitive cellular samples require defined workflows, controlled conditions and clear documentation to preserve sample utility for downstream cellular and molecular endpoints.
PBMC Processing and Biobanking at Scale
In this program, 360biolabs managed more than 22,000 units throughout the study. Chain-of-custody documentation was maintained through the Laboratory Information Management System (LIMS), alongside database entry, data management and controlled biobanking.
Frozen sample storage was supported by 24/7 temperature monitoring and backup power infrastructure. This helped protect sample integrity across processing, storage and onward shipment to third-party laboratories and sponsor-designated facilities.
Why Integration Matters for Early-Phase Decisions
Early-phase programs often operate with limited sample availability, compressed timelines and high decision pressure. Fragmented execution can increase handoffs and make endpoint interpretation harder.
An integrated bioanalytical and central laboratory model can support:
- Fewer operational handoffs between sample collection, processing, storage, analysis and shipment;
- Consistent sample handling across PK, PD, immunogenicity, biomarker and cellular endpoints;
- Defined workflows for PBMC processing, cryogenic storage and controlled sample logistics;
- Faster study readiness when existing validated, qualified or verified methods are appropriate;
- Clearer coordination between scientific teams, clinical sites, project management and quality review;
- Reliable data packages for sponsor decision-making.
This is particularly important for early-phase studies in Australia, where sponsors may seek efficient study start-up, recognised quality standards and practical laboratory support close to clinical sites.
Every Sample Counts
Every sample represents a limited opportunity to answer a scientific question. In complex autoimmune studies, a single sample may support multiple endpoints across exposure, response, immune activity and exploratory biology.
That is why sample planning, documentation and logistics are not secondary tasks. They are part of the scientific strategy. From kit design to LIMS accessioning, from PBMC processing to biobank monitoring, each step affects the quality and usefulness of the final data.
For 360biolabs, this is central to the decade-long commitment to enabling future medicines. Science-driven execution means designing the analytical and operational pathway so every sample can contribute to the next development decision.
A Decade of Enabling Future Medicines
Over ten years, 360biolabs has supported early-phase programs across PK, PD, immunogenicity, biomarkers, vaccines, infectious diseases, central laboratory services and specialised sample handling.
The work continues to evolve with therapeutic complexity. As modalities advance, early-phase studies increasingly need integrated scientific thinking, practical logistics and quality-focused delivery.
360biolabs brings these elements together for sponsors planning early-phase clinical studies in Australia. The aim remains clear: provide reliable, high-quality data that helps bring future medicines closer to the patients who need them.
Interested in discussing for your next early-phase clinical study.